ST
ALXN

Spot Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

Spot Trading’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$6.55M Sell
46,700
-29,200
-38% -$3.97M 0.11% 194
2017
Q2 		$9.23M Buy
75,900
+69,700
+1,124% +$8.11M 0.18% 92
2017
Q1 		$752K Sell
6,200
-45,300
-88% -$5.84M 0.03% 943
2016
Q4 		$6.3M Buy
51,500
+48,800
+1,807% +$5.97M 0.15% 154
2016
Q3 		$331K Sell
2,700
-70,300
-96% -$9.05M 0.01% 1765
2016
Q2 		$8.52M Sell
73,000
-9,100
-11% -$1.29M 0.15% 145
2016
Q1 		$11.4M Buy
82,100
+68,500
+504% +$10.1M 0.2% 95
2015
Q4 		$2.59M Buy
13,600
+4,800
+55% +$838K 0.03% 839
2015
Q3 		$1.38M Sell
8,800
-5,700
-39% -$1.04M 0.01% 1341
2015
Q2 		$2.62M Buy
14,500
+9,800
+209% +$1.69M 0.02% 972
2015
Q1 		$815K Sell
4,700
-6,800
-59% -$1.23M 0.01% 1755
2014
Q4 		$2.13M Sell
11,500
-100
-0.9% -$18.5K 0.01% 1354
2014
Q3 		$1.92M Buy
11,600
+300
+3% +$49.3K 0.01% 1582
2014
Q2 		$1.77M Buy
11,300
+2,400
+27% +$379K 0.01% 1740
2014
Q1 		$1.35M Sell
8,900
-7,200
-45% -$1.14M 0.01% 1812
2013
Q4 		$2.14M Sell
16,100
-21,000
-57% -$2.52M 0.01% 1460
2013
Q3 		$4.31M Buy
37,100
+22,100
+147% +$2.42M 0.03% 825
2013
Q2 		$1.38M Buy
+15,000
New +$1.45M 0.01% 1664

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Spot Trading's ALXN Position: Q3 2017 in Review

Spot Trading increased its Alexion Pharmaceuticals (ALXN) stake by 17% in Q3 2017, buying an estimated $872K and bringing the position to 43,678 shares worth $6.13M. The position accounts for 0.11% of the portfolio, ranked #216.

Spot Trading first reported a position in ALXN in Q3 2013 and has held it in 9 quarters since. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Spot Trading held 43,678 shares of Alexion Pharmaceuticals worth $6.13M as of Q3 2017.
  • Spot Trading bought 6,422 Alexion Pharmaceuticals shares in Q3 2017, an estimated $872K.
  • Alexion Pharmaceuticals made up 0.11% of Spot Trading's portfolio in Q3 2017, its #216 holding.
  • Spot Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and has held it in 9 quarters since.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.